Europe Genetic Testing Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2022 –2029 |
 Marktgröße (Basisjahr) | USD 4,344.02 Billion |
 Marktgröße (Prognosejahr) | USD 12,730.46 Billion |
 CAGR |
% |
| Wichtige Marktteilnehmer |
>Europäischer Markt für genetische Tests, nach Typ (Trägertests, diagnostische Tests, pränatale Tests, Neugeborenen-Screening, prädiktive und präsymptomatische Tests, andere Typen), Technologie (DNA-Sequenzierung (NGS-basierte Tests), Polymerase-Kettenreaktion, Microarrays, Gesamtgenomsequenzierung, Fluoreszenz-in-situ-Hybridisierung (FISH), andere), Krankheiten (seltene genetische Störung, Krebs, Mukoviszidose, Sichelzellenanämie, Muskeldystrophie Duchenne, Thalassämie, Huntington-Krankheit, Fragiles-X-Syndrom, Muskeldystrophie Duchenne, andere), Endbenutzer (Krankenhäuser, Kliniken, Diagnosezentren, Privatkliniken, Labordienstleister, private Labore), Branchentrends und Prognose bis 2029
Marktanalyse und Einblicke
Der europäische Markt für genetische Tests wird von Faktoren wie der hohen Prävalenz genetischer Störungen , wachsenden technologischen Fortschritten auf dem Markt für genetische Tests, die die Nachfrage steigern, sowie steigenden Investitionen in Forschung und Entwicklung angetrieben, die zu Marktwachstum führen. Derzeit sind die Gesundheitsausgaben in Industrie- und Schwellenländern gestiegen, was den Herstellern voraussichtlich einen Wettbewerbsvorteil bei der Entwicklung neuer und innovativer Märkte für genetische Tests verschaffen wird. Allerdings sind mit genetischen Tests hohe Kosten verbunden und es gibt strenge regulatorische Rahmenbedingungen für genetische Tests.
Der europäische Marktbericht für genetische Tests enthält Einzelheiten zu Marktanteilen, neuen Entwicklungen und Produktpipeline-Analysen, den Einfluss inländischer und lokaler Marktteilnehmer, analysiert Chancen in Bezug auf neu entstehende Umsatzbereiche, Änderungen der Marktvorschriften, Produktzulassungen, strategische Entscheidungen, Produkteinführungen, geografische Expansionen und technologische Innovationen auf dem Markt. Um die Analyse und das Marktszenario zu verstehen, kontaktieren Sie uns für ein Analystenbriefing. Unser Team wird Ihnen helfen, eine Umsatzauswirkungslösung zu entwickeln, um Ihr gewünschtes Ziel zu erreichen. Die Skalierbarkeit und Geschäftsausweitung der Einzelhandelseinheiten in den Entwicklungsländern verschiedener Regionen und die Partnerschaft mit Lieferanten für den sicheren Vertrieb von Maschinen- und Arzneimittelprodukten sind die Haupttreiber, die die Nachfrage des Marktes im Prognosezeitraum angetrieben haben.
Marktdefinition
Genetische Tests sind medizinische Tests, die Veränderungen in Genen, Chromosomen oder Proteinen feststellen. Das Ergebnis eines genetischen Tests kann eine vermutete genetische Erkrankung bestätigen oder ausschließen oder dabei helfen, die Wahrscheinlichkeit einer Person zu bestimmen, eine genetische Störung zu entwickeln oder weiterzugeben. Derzeit sind über 77.000 genetische Tests im Einsatz und weitere werden entwickelt.
Die zunehmenden Innovationen und Technologien, die steigende Zahl der Marktteilnehmer und die Markteinführung neuer Produkte treiben das Wachstum des europäischen Marktes für Gentests ebenfalls voran.
Es wird erwartet, dass der europäische Markt für genetische Tests im Prognosezeitraum von 2022 bis 2029 an Marktwachstum gewinnt. Data Bridge Market Research analysiert, dass der Markt im Prognosezeitraum von 2022 bis 2029 mit einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 14,6 % wächst und von 4.344,02 Millionen USD im Jahr 2021 auf 12.730,46 Millionen USD im Jahr 2029 ansteigen dürfte.
|
Berichtsmetrik |
Details |
|
Prognosezeitraum |
2022 bis 2029 |
|
Basisjahr |
2021 |
|
Historische Jahre |
2020 |
|
Quantitative Einheiten |
Umsatz in Mio. USD |
|
Abgedeckte Segmente |
Nach Typ (Trägertests, diagnostische Tests, pränatale Tests, Neugeborenen-Screening, prädiktive und präsymptomatische Tests, andere Typen), Technologie (DNA-Sequenzierung (NGS-basierte Tests), Polymerase-Kettenreaktion , Microarrays, Gesamtgenomsequenzierung, Fluoreszenz-in-situ-Hybridisierung (FISH), andere), Krankheiten (seltene genetische Störung, Krebs, Mukoviszidose, Sichelzellenanämie, Muskeldystrophie Duchenne, Thalassämie, Huntington-Krankheit, Fragiles-X-Syndrom, Muskeldystrophie Duchenne, andere), Endbenutzer (Krankenhäuser, Kliniken, Diagnosezentren, Privatkliniken, Labordienstleister, private Labore) |
|
Abgedeckte Länder |
Deutschland, Frankreich, Großbritannien, Italien, Spanien, Russland, Türkei, Belgien, Niederlande, Schweiz, Restliches Europa |
|
Abgedeckte Marktteilnehmer |
Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., PerkinElmer Inc., Illumina, Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., Abbott, Eurofins Scientific, Biocartis, Cepheid (eine Tochtergesellschaft von Danaher), PacBio, BioReference, Natera, Inc. und andere |
Dynamik des europäischen Gentestmarktes
Treiber
- Wachsende Prävalenz genetischer Erkrankungen
Zum Beispiel,
- Laut der Veröffentlichung vom Januar 2019 mit dem Titel „Manifest des Europäischen Brustkrebsrats 2018: Tests zur Vorhersage genetischer Risiken bei Brustkrebs“ sind BRCA1/2-Tests in Großbritannien und anderen europäischen Regionen, die für Krebsvorsorgeuntersuchungen vorgesehen sind, weit verbreitet.
- In der Europäischen Union werden organisierte genetische Testprogramme angeboten, die sicherstellen, dass der Bevölkerung Screening-Dienste hoher Qualität zur Verfügung gestellt werden.
Daher steigt die Nachfrage auf dem Markt für genetische Tests.
- Zunahme der Nutzung von Next-Generation-Sequencing
Da die Genomik-fokussierte Pharmakologie bei der Behandlung verschiedener chronischer Krankheiten, insbesondere Krebs, eine immer größere Rolle spielt, entwickelt sich die Sequenzierung der nächsten Generation (NGS) zu einem leistungsfähigen Instrument, das tiefere und präzisere Einblicke in die molekularen Grundlagen einzelner Tumore und spezifischer Rezeptoren bietet.
NGS bietet im Vergleich zu herkömmlichen Methoden Vorteile in puncto Genauigkeit, Sensibilität und Geschwindigkeit und hat das Potenzial, die Onkologie erheblich zu verändern. Da NGS mehrere Gene in einem einzigen Test untersuchen kann, ist es nicht mehr erforderlich, mehrere Tests anzuordnen, um die ursächliche Mutation zu identifizieren.
Zum Beispiel,
- NGS wurde auch zur umfassenden Profilierung der Pharmakogenetik mit Relevanz für die Pharmakokinetik und Pharmakodynamik von Arzneimitteln untersucht. Erste Berichte aus dem Jahr 2017 deuten darauf hin, dass diese Technologie ein zuverlässiges und effizientes Instrument zur Entdeckung sowohl häufiger als auch seltener genetischer Variationen in diesen Genen darstellen könnte.
Daher ist zu erwarten, dass dies als Wachstumsmotor für den Markt für genetische Tests wirken wird.
Gelegenheiten
-
Intensivierung von Forschung und Entwicklung
Zum Beispiel,
-
Laut einer Veröffentlichung aus dem Jahr 2020 mit dem Titel „Verfügbarkeit und Finanzierung der klinischen Genomsequenzierung weltweit“ wird in vielen europäischen Ländern außer dem Vereinigten Königreich die Verfügbarkeit genetischer Tests zur Förderung des Wachstums der NGS (Next Generation Sequencing) und der Genommedizin zunehmend erhöht.
-
Steigendes verfügbares Einkommen
Die Ausgaben eines Landes für das Gesundheitswesen und deren Wachstumsrate im Laufe der Zeit hängen von einer Vielzahl wirtschaftlicher und sozialer Faktoren ab, darunter den Finanzierungsvereinbarungen und der Organisationsstruktur des Gesundheitssystems. Insbesondere besteht ein starker Zusammenhang zwischen dem Gesamteinkommensniveau eines Landes und den Ausgaben der Bevölkerung dieses Landes für die Gesundheitsversorgung.
Darüber hinaus werden die strategischen Initiativen der wichtigsten Marktakteure dem Markt für Gentests im Prognosezeitraum 2022–2029 strukturelle Integrität und Zukunftschancen verleihen.
Einschränkungen/Herausforderungen
- Hohe Kosten für genetische Tests
Genetische Tests können teuer sein und werden von manchen Krankenkassen nicht übernommen. Die Kosten der zahlreichen genetischen Tests unterscheiden sich je nach der Krankheit, auf die getestet wird.
Laut Breastcancer.org können die Kosten für genetische Krebstests stark variieren und zwischen 300 und 5.000 US-Dollar liegen. Wie viel genetische Tests kosten, hängt von der Art des Tests und seiner Komplexität ab.
Genetische Tests können zwischen 100 und über 2.000 Dollar kosten, je nach Art und Komplexität des Tests. Wenn mehr als ein Test erforderlich ist oder mehrere Familienmitglieder getestet werden müssen, um ein aussagekräftiges Ergebnis zu erhalten, steigen die Kosten. Die Kosten für Neugeborenen-Screenings variieren je nach Bundesstaat.
Auswirkungen von Covid-19 auf den europäischen Markt für Gentests
COVID-19 hat sich positiv auf den Markt ausgewirkt, da viele genetische und serologische Tests auf COVID-19 durchgeführt wurden, was die Nachfrage nach genetischen Tests in diesem Zeitraum erhöht.
Jüngste Entwicklung
- Im Dezember 2021 gab Thermo Fisher Scientific Inc. bekannt, dass es die Übernahme von PPD, Inc., einem weltweit führenden Anbieter klinischer Forschungsdienstleistungen für die Biopharma- und Biotech-Industrie, für 17,4 Milliarden US-Dollar abgeschlossen hat. Diese Übernahme trug dazu bei, mehr Umsatz zu generieren und das Marktwachstum anzukurbeln.
Marktumfang für genetische Tests in Europa
Der europäische Markt für genetische Tests ist nach Typ, Technologie, Krankheiten und Endnutzer segmentiert. Das Wachstum dieser Segmente hilft Ihnen bei der Analyse schwacher Wachstumssegmente in den Branchen und bietet den Benutzern einen wertvollen Marktüberblick und Markteinblicke, um strategische Entscheidungen zur Identifizierung der wichtigsten Marktanwendungen zu treffen.
Typ
- Diagnostische Tests
- Pränatale Tests
- Neugeborenen-Screening
- Prädiktive und präsymptomatische Tests
- Trägertests
- Andere Typen
Auf der Grundlage des Typs ist der europäische Markt für genetische Tests in diagnostische Tests, pränatale Tests, Neugeborenen-Screening, prädiktive und präsymptomatische Tests, Trägertests und andere Typen segmentiert.
Technologie
- Polymerase-Kettenreaktion
- DNA-Sequenzierung (NGS-basierte Tests)
- Sequenzierung des gesamten Genoms
- Mikroarrays
- Fluoreszenz-in-situ-Hybridisierung (FISH)
- Sonstiges
Auf der Grundlage der Technologie ist der europäische Markt für genetische Tests in DNA-Sequenzierung (NGS-basierte Tests), Polymerase-Kettenreaktion, Microarrays, Gesamtgenomsequenzierung, Fluoreszenz-in-situ-Hybridisierung (FISH) und Sonstiges segmentiert.
Krankheiten
- Krebs
- Sichelzellenanämie
- Thalassämie
- Seltene genetische Störung
- Fragiles X-Syndrom
- Muskeldystrophie Duchenne
- Huntington-Krankheit
- Mukoviszidose
- Sonstiges
Auf der Grundlage von Krankheiten ist der europäische Markt für genetische Tests in seltene genetische Störungen, Krebs, Mukoviszidose, Sichelzellenanämie, Muskeldystrophie Duchenne, Thalassämie, Huntington-Krankheit, Fragiles-X-Syndrom und Sonstiges segmentiert.
Endbenutzer
- Krankenhäuser
- Kliniken
- Diagnostikzentren
- Private Kliniken
- Labordienstleister
- Private Labore
Auf der Grundlage der Endbenutzer ist der europäische Markt für genetische Tests in Krankenhäuser, Kliniken, Diagnosezentren, Privatkliniken, Labordienstleister und private Labore segmentiert.
Regionale Analyse/Einblicke zum genetischen Testmarkt
Der Markt für genetische Tests wird analysiert und es werden Einblicke in die Marktgröße und Trends nach Land, Typ, Technologie, Krankheiten und Endbenutzer wie oben angegeben bereitgestellt.
Deutschland ist aufgrund der zunehmenden Verbreitung genetischer Störungen in der Bevölkerung dieser Länder das dominierende Land auf dem Markt. Und es dominiert den Markt für genetische Tests in Bezug auf Marktanteil und Marktumsatz und wird seine Dominanz im Prognosezeitraum weiter ausbauen. Dies ist auf genetische Defekte und Chromosomenaberrationen in der Bevölkerung dieser Regionen zurückzuführen und die schnelle Entwicklung der Forschung beflügelt den Markt.
Der Länderabschnitt des Berichts enthält auch Angaben zu einzelnen marktbeeinflussenden Faktoren und Änderungen der Marktvorschriften, die sich auf die aktuellen und zukünftigen Markttrends auswirken. Datenpunkte wie Neu- und Ersatzverkäufe, demografische Daten des Landes, Krankheitsepidemiologie und Import- und Exportzölle sind einige der wichtigsten Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Darüber hinaus werden bei der Prognoseanalyse der Länderdaten die Präsenz und Verfügbarkeit globaler Marken und ihre Herausforderungen aufgrund der hohen Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen der Vertriebskanäle berücksichtigt.
Wettbewerbsumfeld und Analyse der Marktanteile für genetische Tests
Die Wettbewerbslandschaft auf dem Markt für genetische Tests liefert Einzelheiten zu den Wettbewerbern. Zu den enthaltenen Einzelheiten gehören Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, globale Präsenz, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen auf den Markt für genetische Tests.
Zu den wichtigsten Akteuren auf dem Markt für genetische Tests zählen unter anderem Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., Abbott, Eurofins Scientific, Biocartis, Cepheid (eine Tochtergesellschaft von Danaher), PacBio, BioReference, Natera, Inc.
Forschungsmethodik
Die Datenerfassung und die Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Die wichtigste Forschungsmethode, die das DBMR-Forschungsteam verwendet, ist die Datentriangulation, die Data Mining, Analyse der Auswirkungen von Datenvariablen auf den Markt und primäre (Branchenexperten-)Validierung umfasst. Abgesehen davon umfassen die Datenmodelle ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, einen Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Firmenmarktanteilsanalyse, Messstandards, globale vs. regionale und Lieferantenanteilsanalyse. Bitte fordern Sie bei weiteren Fragen einen Analystenanruf an.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE GENETIC TESTING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 STRATEGIC INITIATIVES:
4.4 CONCLUSION:
4.5 INDUSTRY INSIGHTS
4.5.1 CANCER GENETICS RISK ASSESSMENT AND COUNSELING
4.5.2 GENETIC TESTS PRICING
4.5.3 KEY INSIGHTS
5 EPIDERMIOLOGY
6 EUROPE GENETIC TESTING MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF GENETIC DISORDERS
7.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING
7.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER
7.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION
7.2 RESTRAINTS
7.2.1 HIGH COST OF GENETIC TESTING
7.2.2 CYBER SECURITY CONCERNS IN GENOMICS
7.3 OPPORTUNITIES
7.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
7.3.2 TECHNOLOGICAL ADVANCEMENT
7.3.3 INCREASING RESEARCH AND DEVELOPMENT
7.3.4 RISING DISPOSABLE INCOME
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING
7.4.2 STRINGENT REGULATION POLICY
8 EUROPE GENETIC TESTING MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIAGNOSTIC TESTING
8.3 PRENATAL TESTING
8.3.1 NON-INVASIVE SCREENING
8.3.1.1 BY SCREENING METHOD
8.3.1.1.1 WHOLE GENOME SEQUENCING
8.3.1.1.2 COUNTING OF CFDNA FRAGMENTS
8.3.1.1.3 OTHERS
8.3.1.2 BY CONDITION
8.3.1.2.1 TRISOMY 21
8.3.1.2.2 KLINEFELTER SYNDROME
8.3.1.2.3 JACOBS SYNDROME
8.3.1.2.4 CYSTIC FIBROSIS
8.3.1.2.5 TURNER SYNDROME
8.3.1.2.6 TRISOMY 18
8.3.1.2.7 HEMOPHILIA
8.3.1.2.8 TRISOMY 13
8.3.1.2.9 MICRODELETION SYNDROME
8.3.1.2.10 FETAL GENDER
8.3.1.2.11 OTHERS
8.3.1.3 BY SCREENING TYPE
8.3.1.3.1 CARRIER SEQUENCING
8.3.1.3.2 SEQUENTIAL SEQUENCING
8.3.2 MATERNAL SERUM QUAD SCREENING
8.4 NEW BORN SCREENING
8.4.1.1 SICKLE CELL DISEASE
8.4.1.2 CONGENITAL HYPOTHYROIDISM
8.4.1.3 PHENYLKETONURIA (PKU)
8.4.1.4 GALACTOSEMIA
8.4.1.5 MAPLE SYRUP URINE DISEASE
8.4.1.6 OTHERS
8.5 PREDICTIVE AND PRESYMPTOMATIC TESTING
8.6 CARRIER TESTING
8.6.1 BY TEST TYPE
8.6.1.1 MOLECULAR SCREENING TEST
8.6.1.2 BIOCHEMICAL SCREENING TEST
8.6.2 BY TYPE
8.6.2.1 EXPANDED CARRIER SCREENING
8.6.2.1.1 PREDESIGNED PANEL TESTING
8.6.2.1.2 CUSTOM-MADE PANEL TESTING
8.6.2.2 TARGETED DISEASE CARRIER SCREENING
8.6.2.2.1 BY MEDICAL CONDITION
8.6.2.2.2 HEMATOLOGICAL CONDITIONS
8.6.2.2.3 PULMONARY CONDITIONS
8.6.2.2.4 NEUROLOGICAL CONDITIONS
8.6.2.2.5 OTHER CONDITIONS
8.7 OTHER TYPES
9 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 POLYMERASE CHAIN REACTION
9.2.1 REAL-TIME PCR (QPCR)
9.2.2 DIGITAL PCR (DPCR)
9.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR)
9.2.4 HOT-START PCR
9.2.5 MULTIPLEX PCR
9.2.6 OTHER PCR
9.3 DNA SEQUENCING (NGS-BASED TESTING)
9.3.1 NEXT GENERATION SEQUENCING (NGS)
9.3.2 SANGER SEQUENCING (SINGLE GENE)
9.3.3 OTHER
9.4 WHOLE GENOME SEQUENCING
9.5 MICROARRAYS
9.5.1 DNA MICROARRAYS
9.5.2 PROTEIN MICROARRAYS
9.5.3 OTHER MICROARRAYS
9.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
9.7 OTHERS
10 EUROPE GENETIC TESTING MARKET, BY DISEASES
10.1 OVERVIEW
10.2 CANCER
10.2.1 BREAST
10.2.2 COLON
10.2.3 LUNG
10.2.4 PROSTATE
10.2.5 OTHERS
10.3 SICKLE CELL ANEMIA
10.4 THALASSEMIA
10.5 RARE GENETIC DISORDER
10.5.1 TRISOMY 21
10.5.2 MONOSOMY X
10.5.3 TRISOMY 13
10.5.4 MICRODELETION SYNDROME
10.5.5 TRISOMY 18
10.5.6 OTHERS
10.6 FRAGILE X SYNDROME
10.7 DUCHENNE MUSCULAR DYSTROPHY
10.8 HUNTINGTON'S DISEASE
10.9 CYSTIC FIBROSIS
10.1 OTHERS
11 EUROPE GENETIC TESTING MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 DIAGNOSTIC CENTERS
11.5 PRIVATE CLINICS
11.6 LABORATORY SERVICE PROVIDERS
11.7 PRIVATE LABORATORIES
12 EUROPE GENETIC TESTING MARKET, BY REGION
12.1 EUROPE
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K.
12.1.4 RUSSIA
12.1.5 ITALY
12.1.6 SPAIN
12.1.7 TURKEY
12.1.8 NETHERLANDS
12.1.9 SWITZERLAND
12.1.10 BELGIUM
12.1.11 REST OF EUROPE
13 EUROPE GENETIC TESTING MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 WOT ANALYSIS
15 COMPANY PROFILE
15.1 ILLUMINA, INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 COMPANY SHARE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.1.4.1 ACQUISITION
15.1.4.2 COLLABORATION
15.2 CEPHEID
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.2.5.1 BUSINEES EXPANSION
15.3 FULGENT GENETICS
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.3.5.1 ACQUISITION
15.4 PERKINELMER INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.4.5.1 PRODUCT LAUNCH
15.5 THERMO FISHER SCIENTIFIC INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.5.5.1 COLLABORATION
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 BIOCARTIS
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.7.4.1 PARTNERSHIP
15.7.4.2 AGREEMENT
15.8 BIO-HELIX
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BIO-RAD LABORATORIES, INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.9.4.1 ACQUISITION
15.9.4.2 PARTNERSHIP
15.1 BIOREFERENCE
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.10.4.1 ACQUISITION
15.11 ELITECHGROUP
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.11.3.1 PRODUCT LAUNCH
15.11.3.2 BUSINESS EXPANSION
15.12 EUROFINS SCIENTIFIC
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.12.4.1 PRODUCT LAUNCH
15.13 EUGENE LABS
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 F. HOFFMANN-LA ROCHE LTD)
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS (PARENT COMPANY)
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.14.4.1 PRODUCT LAUNCH
15.15 GENES2ME
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 INVITAE CORPORATION
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENTS
15.17 MAPMYGENOME
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 MEDGENOME
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 MYRIAD GENETICS
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.2 NATERA, INC.
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.20.3.1 PARTNERSHIP
15.21 OTOGENRTICS
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENT
15.22 PACBIO
15.22.1 COMPANY SNAPSHOT
15.22.2 REVENUE ANALYSIS
15.22.3 PRODUCT PORTFOLIO
15.22.4 RECENT DEVELOPMENT
15.23 QIAGEN
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENTS
15.23.3.1 PARTNERSHIP
15.23.3.2 PRODUCT LAUNCH
15.24 SEMA4 OPCO, INC.
15.24.1 COMPANY SNAPSHOT
15.24.2 REVENUE ANALYSIS
15.24.3 PRODUCT PORTFOLIO
15.24.4 RECENT DEVELOPMENT
15.25 SORENSON GENOMICS
15.25.1 COMPANY SNAPSHOT
15.25.2 PRODUCT PORTFOLIO
15.25.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 3 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 4 EUROPE DIAGNOSTIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 8 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 9 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 10 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 11 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 12 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 14 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 15 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 16 EUROPE NEW BORN SCREENING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 EUROPE PREDICTIVE AND PRESYMPTOMATIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 21 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 22 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 23 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 25 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 26 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 28 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 29 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE OTHER TYPES IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 32 EUROPE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 34 EUROPE DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 36 EUROPE WHOLE GENOME SEQUENCING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE MICROARRAYS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 EUROPE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 39 EUROPE FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 EUROPE OTHERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 42 EUROPE CANCER IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 44 EUROPE SICKLE CELL ANEMIA IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 EUROPE THALASSEMIA IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 46 EUROPE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 47 EUROPE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 48 EUROPE FRAGILE X SYNDROME IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 49 EUROPE DUCHENNE MUSCULAR DYSTROPHY IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 50 EUROPE HUNTINGTON'S DISEASE IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 51 EUROPE CYSTIC FIBROSIS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 52 EUROPE OTHERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 53 EUROPE GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 EUROPE HOSPITALS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 55 EUROPE CLINICS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 56 EUROPE DIAGNOSTIC CENTERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 57 EUROPE PRIVATE CLINICS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 58 EUROPE LABORATORY SERVICE PROVIDERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 59 EUROPE PRIVATE LABORATORIES IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 60 EUROPE GENETIC TESTING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 61 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 63 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 64 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 66 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 67 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 68 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 69 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 70 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 71 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 72 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 73 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 74 EUROPE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 76 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 77 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 78 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 80 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 81 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 83 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 84 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 85 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 86 EUROPE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 87 EUROPE DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 88 EUROPE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 89 EUROPE GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 90 EUROPE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 91 EUROPE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 92 EUROPE GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 GERMANY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 GERMANY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 95 GERMANY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 96 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 98 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 99 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 100 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 101 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 102 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 103 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 104 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 105 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 106 GERMANY NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 108 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 109 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 110 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 112 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 113 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 115 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 116 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 117 GERMANY GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 118 GERMANY POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 119 GERMANY DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 120 GERMANY MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 121 GERMANY GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 122 GERMANY RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 123 GERMANY CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 124 GERMANY GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 125 FRANCE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 FRANCE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 127 FRANCE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 128 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 130 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 131 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 132 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 133 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 134 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 135 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 136 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 137 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 138 FRANCE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 140 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 141 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 142 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 144 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 145 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 147 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 148 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 149 FRANCE GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 150 FRANCE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 151 FRANCE DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 152 FRANCE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 153 FRANCE GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 154 FRANCE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 155 FRANCE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 156 FRANCE GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 157 U.K. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 U.K. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 159 U.K. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 160 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 162 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 163 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 164 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 165 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 166 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 167 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 168 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 169 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 170 U.K. NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 171 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 172 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 173 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 174 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 176 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 177 U.K. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 U.K. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 179 U.K. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 180 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 181 U.K. GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 182 U.K. POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 183 U.K. DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 184 U.K. MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 185 U.K. GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 186 U.K. RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 187 U.K. CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 188 U.K. GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 189 RUSSIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 190 RUSSIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 191 RUSSIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 192 RUSSIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 RUSSIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 194 RUSSIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 195 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 196 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 197 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 198 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 199 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 200 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 201 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 202 RUSSIA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 203 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 204 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 205 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 206 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 207 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 208 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 209 RUSSIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 RUSSIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 211 RUSSIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 212 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 213 RUSSIA GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 214 RUSSIA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 215 RUSSIA DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 216 RUSSIA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 217 RUSSIA GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 218 RUSSIA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 219 RUSSIA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 220 RUSSIA GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 221 ITALY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 ITALY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 223 ITALY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 224 ITALY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 225 ITALY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 226 ITALY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 227 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 228 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 229 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 230 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 231 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 232 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 233 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 234 ITALY NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 235 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 236 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 237 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 238 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 239 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 240 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 241 ITALY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 ITALY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 243 ITALY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 244 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 245 ITALY GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 246 ITALY POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 247 ITALY DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 248 ITALY MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 249 ITALY GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 250 ITALY RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 251 ITALY CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 252 ITALY GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 253 SPAIN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 254 SPAIN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 255 SPAIN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 256 SPAIN PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 257 SPAIN PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 258 SPAIN PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 259 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 260 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 261 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 262 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 263 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 264 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 265 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 266 SPAIN NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 267 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 268 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 269 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 270 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 271 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 272 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 273 SPAIN EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 274 SPAIN EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 275 SPAIN EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 276 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 277 SPAIN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 278 SPAIN POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 279 SPAIN DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 280 SPAIN MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 281 SPAIN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 282 SPAIN RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 283 SPAIN CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 284 SPAIN GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 285 TURKEY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 286 TURKEY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 287 TURKEY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 288 TURKEY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 289 TURKEY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 290 TURKEY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 291 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 292 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 293 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 294 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 295 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 296 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 297 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 298 TURKEY NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 299 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 300 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 301 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 302 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 303 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 304 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 305 TURKEY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 306 TURKEY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 307 TURKEY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 308 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 309 TURKEY GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 310 TURKEY POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 311 TURKEY DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 312 TURKEY MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 313 TURKEY GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 314 TURKEY RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 315 TURKEY CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 316 TURKEY GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 317 NETHERLANDS GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 318 NETHERLANDS GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 319 NETHERLANDS GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 320 NETHERLANDS PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 321 NETHERLANDS PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 322 NETHERLANDS PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 323 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 324 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 325 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 326 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 327 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 328 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 329 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 330 NETHERLANDS NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 331 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 332 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 333 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 334 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 335 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 336 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 337 NETHERLANDS EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 338 NETHERLANDS EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 339 NETHERLANDS EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 340 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 341 NETHERLANDS GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 342 NETHERLANDS POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 343 NETHERLANDS DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 344 NETHERLANDS MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 345 NETHERLANDS GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 346 NETHERLANDS RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 347 NETHERLANDS CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 348 NETHERLANDS GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 349 SWITZERLAND GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 350 SWITZERLAND GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 351 SWITZERLAND GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 352 SWITZERLAND PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 353 SWITZERLAND PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 354 SWITZERLAND PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 355 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 356 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 357 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 358 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 359 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 360 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 361 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 362 SWITZERLAND NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 363 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 364 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 365 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 366 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 367 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 368 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 369 SWITZERLAND EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 370 SWITZERLAND EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 371 SWITZERLAND EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 372 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 373 SWITZERLAND GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 374 SWITZERLAND POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 375 SWITZERLAND DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 376 SWITZERLAND MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 377 SWITZERLAND GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 378 SWITZERLAND RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 379 SWITZERLAND CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 380 SWITZERLAND GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 381 BELGIUM GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 382 BELGIUM GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 383 BELGIUM GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 384 BELGIUM PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 385 BELGIUM PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 386 BELGIUM PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 387 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 388 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 389 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 390 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 391 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 392 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 393 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 394 BELGIUM NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 395 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 396 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 397 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 398 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 399 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 400 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 401 BELGIUM EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 402 BELGIUM EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 403 BELGIUM EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 404 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 405 BELGIUM GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 406 BELGIUM POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 407 BELGIUM DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 408 BELGIUM MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 409 BELGIUM GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 410 BELGIUM RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 411 BELGIUM CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 412 BELGIUM GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 413 REST OF EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 414 REST OF EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 415 REST OF EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
Abbildungsverzeichnis
FIGURE 1 EUROPE GENETIC TESTING MARKET: SEGMENTATION
FIGURE 2 EUROPE GENETIC TESTING MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE GENETIC TESTING MARKET: DROC ANALYSIS
FIGURE 4 EUROPE GENETIC TESTING MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE GENETIC TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE GENETIC TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE GENETIC TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE GENETIC TESTING MARKET: APPLICATION COVERAGE GRID
FIGURE 9 EUROPE GENETIC TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE GENETIC TESTING MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE EUROPE GENETIC TESTING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 DIAGNOSTIC TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE GENETIC TESTING MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE GENETIC TESTING MARKET AND ASIA-PACIFIC EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE GENETIC TESTING MARKET
FIGURE 15 EUROPE GENETIC TESTING MARKET: BY TYPE, 2021
FIGURE 16 EUROPE GENETIC TESTING MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 17 EUROPE GENETIC TESTING MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 18 EUROPE GENETIC TESTING MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, 2021
FIGURE 20 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, 2022-2029 (USD MILLION)
FIGURE 21 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 22 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 23 EUROPE GENETIC TESTING MARKET: BY DISEASES, 2021
FIGURE 24 EUROPE GENETIC TESTING MARKET: BY DISEASES, 2022-2029 (USD MILLION)
FIGURE 25 EUROPE GENETIC TESTING MARKET: BY DISEASES, CAGR (2022-2029)
FIGURE 26 EUROPE GENETIC TESTING MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 27 EUROPE GENETIC TESTING MARKET: BY END USER, 2021
FIGURE 28 EUROPE GENETIC TESTING MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 29 EUROPE GENETIC TESTING MARKET: BY END USER, CAGR (2022-2029)
FIGURE 30 EUROPE GENETIC TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 EUROPE GENETIC TESTING MARKET: SNAPSHOT (2021)
FIGURE 32 EUROPE GENETIC TESTING MARKET: BY COUNTRY (2021)
FIGURE 33 EUROPE GENETIC TESTING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 34 EUROPE GENETIC TESTING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 35 EUROPE GENETIC TESTING MARKET: BY TYPE (2022-2029)
FIGURE 36 EUROPE GENETIC TESTING MARKET: COMPANY SHARE 2021 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
